510(k) device
HistoSonics® Planning Tool
HistoSonics, Inc. · Radiological Image Processing Software For Ablation Therapy Planning And Evaluation (QTZ, Class II) · First FDA decision May 29, 2026, newest May 29, 2026Liver disease and liver cancerTumor ablation
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
14
Naming "HistoSonics"
MAUDE reports
2
Brand "HistoSonics", since 2015
PubMed studies
8
Mentioning "HistoSonics"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing HistoSonics® Planning Tool
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K252947 · Decided May 29, 2026 · 256 days after receipt
Device type: Radiological Image Processing Software For Ablation Therapy Planning And Evaluation (QTZ) · Radiology & Imaging
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Psychiatric Diagnostic Evaluation and Psychotherapy ServicesLocal determinationIn effectL33252First Coast Service Options, Inc.Updated Jun 19, 2020
Clinical trials
Device studies on ClinicalTrials.gov that name "HistoSonics", any status and sponsor, newest update first.
- Histotripsy for Renal Cell CarcinomaRecruiting
The University of Hong KongAcademic, hospital or other
NCT07943143 · 15 participants (planned) · Start Oct 13, 2026 · Primary completion Oct 30, 2028
Device: HistoSonics® Edison System (US) · For: Localised or Metastatic Renal Cell Carcinoma
Sites: Hong Kong, Hong Kong
- Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver MetastasisActive, not recruiting
Case Comprehensive Cancer CenterAcademic, hospital or other
NCT07044362 · 2 participants · Start Nov 19, 2025 · Primary completion Dec 1, 2026
Device: HistoSonics Edison® System · For: Colorectal Cancer; Liver Metastases; Liver Cancer
Sites: Cleveland, Ohio
HistoSonics, Inc.Not on our public-company list
NCT06486454 · 5,000 participants (planned) · Start Oct 14, 2024 · Primary completion Nov 2034
Device: HistoSonics Edison System · For: Liver Neoplasms; Primary Liver Cancer; Secondary Liver Cancer and 2 more
Sites: Mobile, Alabama; Fullerton, California; Los Angeles, California · 35 sites in all
11 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "HistoSonics", and for the whole product code for context.
This brand
2 reports: 0 malfunction, 2 injury, 0 death
Whole product code QTZ
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
- HISTOSONICS EDISONInjury
MW5187922 · Received May 11, 2026 · Event dated Mar 23, 2026
Device type: Focused Ultrasound System For Non-Thermal, Mechanical Tissue Ablation (QGM)
Device problem as coded: Improper or Incorrect Procedure or Method
Patient problem as coded: Insufficient Information
- HISTOSONICS EDISONInjury
MW5187923 · Received May 11, 2026 · Event dated Mar 23, 2026
Device type: Focused Ultrasound System For Non-Thermal, Mechanical Tissue Ablation (QGM)
Device problem as coded: Improper or Incorrect Procedure or Method
Patient problem as coded: Insufficient Information
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "HistoSonics"[tiab]. The summary above synthesizes these.
- Noninvasive thyroid histotripsy treatment: proof of concept study in a porcine model.
Swietlik JF, Mauch SC, Knott EA, et al. · Int J Hyperthermia · 2021Research Support, Non-U.S. Gov't
- First-in-man histotripsy of hepatic tumors: the THERESA trial, a feasibility study.
Vidal-Jove J, Serres X, Vlaisavljevich E, et al. · Int J Hyperthermia · 2022Multicenter Study, Research Support, Non-U.S. Gov't
- Aberration correction expands the treatment envelope for histotripsy in the liver.
Yeats E, Lu N, Sukovich J, et al. · Phys Med Biol · 2025Research Support, N.I.H., Extramural
- Treatment of Primary Solid Renal Tumours Using Histotripsy: Study Protocol for the CAIN Feasibility Trial.
Wah TM, Amaral JF, Laeseke PF · Cardiovasc Intervent Radiol · 2025Clinical Trial Protocol
- Robotically Assisted Sonic Therapy (RAST) for Noninvasive Hepatic Ablation in a Porcine Model: Mitigation of Body Wall Damage with a Modified Pulse Sequence.
Longo KC, Knott EA, Watson RF, et al. · Cardiovasc Intervent Radiol · 2019
- Robotically-Assisted Sonic Therapy for Renal Ablation in a Live Porcine Model: Initial Preclinical Results.
Knott EA, Swietlik JF, Longo KC, et al. · J Vasc Interv Radiol · 2019
- Histotripsy in the Management of RCC: A New Frontier in Focused Therapies.
Eigner E, Malshy K, Bandari J, et al. · Clin Genitourin Cancer · 2025Review
- A Multi-centre, Single Arm, Non-randomized, Prospective European Trial to Evaluate the Safety and Efficacy of the HistoSonics System in the Treatment of Primary and Metastatic Liver Cancers (#HOPE4LIVER).
Wah TM, Pech M, Thormann M, et al. · Cardiovasc Intervent Radiol · 2023Multicenter Study
Other devices of this type
Also filed under product code QTZ.
- myAblation Guide (VC10A)Siemens Healthcare GmbH · 510(k) 2026
- VisAble.IOTechsomed · 510(k) 2024
- BioTraceIO Vision (V1.7)Techsomed Medical Technologies · 510(k) 2025
- Artemis, Artemis TPO, Artemis MXEigen · 510(k) 2023
- Ablation-fitR.a.w. S.r.l · 510(k) 2023
- MIM-AblationMim Software, Inc. · 510(k) 2022
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.